Two cases of renal cell cancer during immunobiologic therapy for psoriasis

An Bras Dermatol. 2014 Nov-Dec;89(6):1017-8. doi: 10.1590/abd1806-4841.20143257.

Abstract

Immunobiologic therapy is indicated for severe forms of psoriasis, resistant to conventional therapy. There is growing concern about their safety profile and possible association with cancer development. This article documents two cases of renal cell cancer during treatment with biologic therapy, reviewing what is described in the literature . The risk of solid tumors as a complication of using TNF-alpha inhibitors is controversial. No conclusion can be drawn from the data in the literature, however, we believe that special attention should be given to those with known risk factors for a specific neoplasm.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / adverse effects
  • Carcinoma, Renal Cell / chemically induced*
  • Dermatologic Agents / adverse effects
  • Etanercept
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunologic Factors / adverse effects*
  • Infliximab
  • Kidney Neoplasms / chemically induced*
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor
  • Risk Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Immunoglobulin G
  • Immunologic Factors
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept